BR112022011426A2 - Uso de inibidores de atr em combinação com inibidores de parp - Google Patents
Uso de inibidores de atr em combinação com inibidores de parpInfo
- Publication number
- BR112022011426A2 BR112022011426A2 BR112022011426A BR112022011426A BR112022011426A2 BR 112022011426 A2 BR112022011426 A2 BR 112022011426A2 BR 112022011426 A BR112022011426 A BR 112022011426A BR 112022011426 A BR112022011426 A BR 112022011426A BR 112022011426 A2 BR112022011426 A2 BR 112022011426A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- combination
- cancer
- atr
- rnase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946876P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/064662 WO2021119523A1 (en) | 2019-12-11 | 2020-12-11 | Use of atr inhibitors in combination with parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011426A2 true BR112022011426A2 (pt) | 2022-08-30 |
Family
ID=76316464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011426A BR112022011426A2 (pt) | 2019-12-11 | 2020-12-11 | Uso de inibidores de atr em combinação com inibidores de parp |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210177856A1 (https=) |
| EP (1) | EP4072551A4 (https=) |
| JP (1) | JP2023506787A (https=) |
| KR (1) | KR20220128350A (https=) |
| CN (1) | CN115103677A (https=) |
| AU (1) | AU2020402108A1 (https=) |
| BR (1) | BR112022011426A2 (https=) |
| CA (1) | CA3164203A1 (https=) |
| CL (1) | CL2022001540A1 (https=) |
| IL (1) | IL293810A (https=) |
| MX (1) | MX2022007163A (https=) |
| WO (1) | WO2021119523A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| BR112023024942A2 (pt) * | 2021-06-16 | 2024-02-15 | Repare Therapeutics Inc | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer |
| CN119212710A (zh) * | 2022-04-07 | 2024-12-27 | 修复治疗公司 | 使用atr抑制剂的方法 |
| US20250352539A1 (en) * | 2022-06-15 | 2025-11-20 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2024164089A1 (en) * | 2023-02-09 | 2024-08-15 | Repare Therapeutics Inc. | Use of atr inhibitors in the treatment of cancers with high tumor mutational burden |
| CN117159725B (zh) * | 2023-04-06 | 2024-07-05 | 上海交通大学医学院附属仁济医院 | 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法 |
| WO2024243078A1 (en) * | 2023-05-19 | 2024-11-28 | Leapfrog Bio, Inc. | Hsp90 inhibitors for the treatment of cancer |
| EP4716756A1 (en) * | 2023-05-23 | 2026-04-01 | The Francis Crick Institute Limited | Targets for treatment of alt-positive cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2305221T3 (pl) * | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US11660301B2 (en) * | 2017-02-24 | 2023-05-30 | Bayer Pharma Aktiengesellschaft | Combination of ATR kinase inhibitors with PARP inhibitors |
| AU2019373416A1 (en) * | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
-
2020
- 2020-12-11 EP EP20898316.3A patent/EP4072551A4/en not_active Withdrawn
- 2020-12-11 AU AU2020402108A patent/AU2020402108A1/en not_active Abandoned
- 2020-12-11 KR KR1020227023568A patent/KR20220128350A/ko not_active Withdrawn
- 2020-12-11 US US17/119,512 patent/US20210177856A1/en not_active Abandoned
- 2020-12-11 WO PCT/US2020/064662 patent/WO2021119523A1/en not_active Ceased
- 2020-12-11 MX MX2022007163A patent/MX2022007163A/es unknown
- 2020-12-11 CA CA3164203A patent/CA3164203A1/en active Pending
- 2020-12-11 CN CN202080096191.XA patent/CN115103677A/zh active Pending
- 2020-12-11 BR BR112022011426A patent/BR112022011426A2/pt not_active IP Right Cessation
- 2020-12-11 JP JP2022535631A patent/JP2023506787A/ja active Pending
- 2020-12-11 IL IL293810A patent/IL293810A/en unknown
-
2022
- 2022-06-09 CL CL2022001540A patent/CL2022001540A1/es unknown
-
2023
- 2023-12-12 US US18/537,061 patent/US20240350505A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022007163A (es) | 2022-08-25 |
| AU2020402108A1 (en) | 2022-07-14 |
| WO2021119523A8 (en) | 2021-08-05 |
| EP4072551A4 (en) | 2023-11-15 |
| IL293810A (en) | 2022-08-01 |
| KR20220128350A (ko) | 2022-09-20 |
| US20240350505A1 (en) | 2024-10-24 |
| CA3164203A1 (en) | 2021-06-17 |
| CL2022001540A1 (es) | 2023-01-13 |
| EP4072551A1 (en) | 2022-10-19 |
| CN115103677A (zh) | 2022-09-23 |
| WO2021119523A1 (en) | 2021-06-17 |
| JP2023506787A (ja) | 2023-02-20 |
| US20210177856A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023024942A2 (pt) | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer | |
| BR112022011426A2 (pt) | Uso de inibidores de atr em combinação com inibidores de parp | |
| MX2023011608A (es) | Metodos para inhibir ras. | |
| BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
| MX2020010368A (es) | Compuestos dirigidos a brm y métodos de uso asociados. | |
| DOP2020000154A (es) | Inhibidores pd-1/pd-l1 | |
| BR112018008746A8 (pt) | composições e métodos para a inibição de atividade de arginase | |
| CL2019001711A1 (es) | Composiciones y métodos para inhibir la acción de la arginasa. | |
| UY37803A (es) | Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia | |
| MX2018013847A (es) | Metodos para tratar cancer de piel administrando un inhibidor de pd-1. | |
| BR112015027319A8 (pt) | Métodos e composições para modular a expressão de apolipoproteína (a) | |
| BR112018071023A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose | |
| BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
| BR112015025944A8 (pt) | composição compreendendo inibidores do caminho do hedgehog e uso dos referidos inibidores | |
| MX2018014231A (es) | Metodos y composiciones para tratar canceres resistentes al inhibidor de la via de cinasas proteicas activadas por mitogeno (mapk), no cinasas extracelulares de señal regulada (erk). | |
| MX385750B (es) | Compuestos y métodos para la degradación mejorada de proteinas específicas. | |
| BR112015020290A2 (pt) | métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
| BR112014028991A2 (pt) | triazóis como inibidores de kv3 | |
| BR112015029495A2 (pt) | compostos heterocíclicos como inibidores da via de sinalização hedgehog | |
| BR112018007604A2 (pt) | métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk | |
| CL2022001368A1 (es) | Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| BR112021019703A2 (pt) | Compostos heterocíclicos e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2858 DE 14-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |